Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Open in Screener

TARS

Tarsus Pharmaceuticals Inc

Sep 20 • 04:00PM ET

34.51

Dollar change -0.09
Percentage change -0.26	%

Healthcare • Biotechnology • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: IWM VTI VXF IWO IBB SCHA XPH VTWO IWC IHE

Index	RUT	P/E	-	EPS (ttm)	-4.48	Insider Own	16.43%	Shs Outstand	34.21M	Perf Week	3.76%
Market Cap	1.31B	Forward P/E	-	EPS next Y	-2.37	Insider Trans	-0.72%	Shs Float	31.79M	Perf Month	32.32%
Income	-150.07M	PEG	-	EPS next Q	-0.94	Inst Own	98.60%	Short Float	30.81%	Perf Quarter	32.32%
Sales	83.37M	P/S	15.75	EPS this Y	18.24%	Inst Trans	1.78%	Short Ratio	12.55	Perf Half Y	2.53%
Book/sh	6.63	P/B	5.20	EPS next Y	37.37%	ROA	-53.05%	Short Interest	9.79M	Perf Year	106.03%
Cash/sh	8.51	P/C	4.06	EPS next 5Y	-	ROE	-75.04%	52W Range	12.57 - 42.50	Perf YTD	70.42%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-132.82%	ROI	-46.34%	52W High	-18.80%	Beta	1.06
Dividend TTM	-	Quick Ratio	6.99	Sales past 5Y	-17.43%	Gross Margin	92.06%	52W Low	174.54%	ATR (14)	1.84
Dividend Ex-Date	-	Current Ratio	7.03	EPS Y/Y TTM	-31.81%	Oper. Margin	-187.55%	RSI (14)	67.24	Volatility	5.98% 6.34%
Employees	244	Debt/Eq	0.29	Sales Y/Y TTM	566.99%	Profit Margin	-180.00%	Recom	1.38	Target Price	59.00
Option/Short	Yes / Yes	LT Debt/Eq	0.28	EPS Q/Q	24.88%	Payout	-	Rel Volume	1.53	Prev Close	34.60
Sales Surprise	26.22%	EPS Surprise	4.66%	Sales Q/Q	-	Earnings	Aug 08 AMC	Avg Volume	780.67K	Price	34.51
SMA20	17.11%	SMA50	25.97%	SMA200	18.30%	Trades		Volume	1,197,222	Change	-0.26%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-20-23	Initiated	Goldman	Neutral	$19
Jul-18-23	Initiated	William Blair	Outperform	$44
May-18-23	Initiated	Guggenheim	Buy
Aug-01-22	Initiated	Barclays	Overweight	$40
Dec-21-21	Initiated	H.C. Wainwright	Buy	$40
Nov-23-21	Initiated	Oppenheimer	Outperform	$55
Nov-10-20	Initiated	Raymond James	Strong Buy	$39
Nov-10-20	Initiated	Ladenburg Thalmann	Buy	$42
Nov-10-20	Initiated	Jefferies	Buy	$35
Nov-10-20	Initiated	BofA Securities	Buy	$33

Aug-28-24 05:00PM	Tarsus to Participate in Fireside Chat at the 2024 Wells Fargo Securities Healthcare Conference (GlobeNewswire)
Aug-08-24 09:56PM	TARS Stock Earnings: Tarsus Pharmaceuticals Beats EPS, Beats Revenue for Q2 2024 (InvestorPlace) +13.72%
06:05PM	Tarsus Pharmaceuticals, Inc. (TARS) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Tarsus Reports Second Quarter and Year-to-Date 2024 Financial Results and Recent Business Achievements (GlobeNewswire)
Jul-29-24 04:30PM	Tarsus to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024 (GlobeNewswire)
05:00PM	Loading…
May-29-24 05:00PM	Tarsus to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-09-24 05:00PM	Tarsus to Participate in Fireside Chat at the 2024 Bank of America Healthcare Conference (GlobeNewswire) -8.86% +8.70%
12:48PM	Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q1 2024 Earnings Call Transcript (Insider Monkey)
11:06AM	Oppenheimer Adjusts Tarsus Pharmaceuticals Price Target to $61 From $59, Maintains Outperform Rating (MT Newswires)
03:49AM	Tarsus Pharmaceuticals Inc (TARS) Q1 2024 Earnings Call Transcript Highlights: Strategic Growth ... (GuruFocus.com)
May-08-24 08:58PM	TARS Stock Earnings: Tarsus Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
05:40PM	Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Tarsus Reports First Quarter 2024 Financial Results and Recent Business Achievements (GlobeNewswire)
May-06-24 09:55AM	Does Tarsus Pharmaceuticals (TARS) Have the Potential to Rally 38.7% as Wall Street Analysts Expect? (Zacks)
May-01-24 05:00PM	Tarsus to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024 (GlobeNewswire) +6.59%
08:30AM	Loading…
Apr-23-24 08:30AM	Tarsus Strengthens Financial Position and Refinances Existing Debt with $200 Million Non-dilutive Financing Commitment from Pharmakon (GlobeNewswire)
Apr-09-24 07:35AM	5 Best Biotech ETFs To Buy (Insider Monkey)
Apr-08-24 09:55AM	Wall Street Analysts Predict a 47.12% Upside in Tarsus Pharmaceuticals (TARS): Here's What You Should Know (Zacks)
Apr-04-24 11:33AM	Aggressive Stock Portfolio: 13 Stocks Picked by Analysts (Insider Monkey)
Apr-01-24 12:00PM	Tarsus Pharmaceuticals (TARS) Upgraded to Buy: Here's Why (Zacks)
Mar-06-24 09:55AM	How Much Upside is Left in Tarsus Pharmaceuticals, Inc. (TARS)? Wall Street Analysts Think 37.91% (Zacks)
Mar-05-24 04:30PM	Tarsus to Participate at Upcoming Investor Conferences (GlobeNewswire)
08:30AM	Tarsus Introduces Mite Party Campaign for XDEMVY (lotilaner ophthalmic solution) 0.25% to Educate Consumers about Demodex Blepharitis (GlobeNewswire)
Mar-01-24 12:07AM	Tarsus Announces Pricing of $100.0 Million Public Offering (GlobeNewswire)
Feb-29-24 04:37PM	Tarsus Announces Proposed $100.0 Million Public Offering (GlobeNewswire)
Feb-28-24 12:00PM	Here's Why Tarsus Pharmaceuticals, Inc. (TARS) is a Great Momentum Stock to Buy (Zacks)
09:58AM	Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-27-24 11:13PM	Q4 2023 Tarsus Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) +18.28%
06:34AM	Tarsus Pharmaceuticals Inc (TARS) Reports Robust Q4 and Full-Year 2023 Financial Results (GuruFocus.com)
06:00AM	Tarsus Reports Strong Fourth Quarter and Full-Year 2023 Financial Results and Recent Business Achievements (GlobeNewswire)
08:00AM	Loading…
Feb-22-24 08:00AM	Tarsus Announces Positive Topline Results from Carpo, a Phase 2a Proof-of-Concept Tick-Kill Trial Evaluating TP-05 (lotilaner) for the Prevention of Lyme Disease (GlobeNewswire)
Feb-20-24 05:00PM	Tarsus to Report Fourth Quarter and Full Year 2023 Financial Results on Tuesday, February 27, 2024 (GlobeNewswire)
Jan-31-24 05:00PM	Tarsus to Participate in Fireside Chat at the Sixth Annual Guggenheim Healthcare Talks Conference (GlobeNewswire) +6.17%
Jan-30-24 04:06AM	Tarsus Pharmaceuticals, Inc. (TARS) Moves 8.5% Higher: Will This Strength Last? (Zacks)
Jan-21-24 07:01AM	11 Stocks That Will Make You Rich in 5-10 Years (Insider Monkey)
Dec-21-23 03:32PM	Tarsus Pharmaceuticals Stock Scores Relative Strength Rating Upgrade (Investor's Business Daily)
Dec-11-23 08:00AM	Tarsus Announces Positive Topline Results from the Ersa Phase 2a Clinical Trial Evaluating TP-03 for the Treatment of Meibomian Gland Disease in Patients with Demodex Mites (GlobeNewswire)
Dec-01-23 11:04PM	Insider Sell Alert: Tarsus Pharmaceuticals Inc's Dianne Whitfield Offloads 8,355 Shares (GuruFocus.com)
Nov-12-23 12:15PM	Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-09-23 04:05PM	Tarsus Reports Third Quarter 2023 Financial Results and Recent Business Achievements (GlobeNewswire) -5.86% +12.20%
Nov-01-23 06:35PM	Tarsus to Report Third Quarter 2023 Financial Results on Thursday, November 9, 2023 (GlobeNewswire)
Sep-06-23 08:00AM	Tarsus to Ring Nasdaq Stock Market Closing Bell in Celebration of the Launch of XDEMVY, the First and Only FDA Approved Treatment for Demodex Blepharitis (GlobeNewswire)
Aug-30-23 04:30PM	Tarsus to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-28-23 10:22AM	15 Most Shorted Stocks That Are Loved By Analysts (Insider Monkey)
Aug-24-23 09:00AM	Now Available XDEMVY (lotilaner ophthalmic solution) 0.25%, the First and Only FDA Approved Treatment for Demodex Blepharitis (GlobeNewswire)
Aug-10-23 04:05PM	Tarsus Reports Second Quarter 2023 Financial Results and Recent Business Achievements (GlobeNewswire)
Aug-03-23 02:14PM	This Tarsus Pharmaceuticals Insider Increased Their Holding In The Last Year (Simply Wall St.)
Aug-01-23 10:30PM	Tarsus Announces Pricing of $100.0 Million Underwritten Public Offering of Common Stock (GlobeNewswire) -16.99% -5.53%
Jul-31-23 04:29PM	Tarsus Announces Proposed $100.0 Million Underwritten Public Offering of Shares of its Common Stock (GlobeNewswire)
Jul-25-23 07:00AM	FDA Approves XDEMVY (lotilaner ophthalmic solution) 0.25% for the treatment of Demodex blepharitis (GlobeNewswire) -24.82%
Jul-20-23 02:04PM	Why Shares of Tarsus Pharmaceuticals Are Up Thursday (Motley Fool) +15.56%
Jul-19-23 08:34PM	Tarsus Pharmaceuticals, Inc. (TARS) Surges 7.8%: Is This an Indication of Further Gains? (Zacks) +7.83%
10:13AM	Oppenheimer Says These 2 Stocks Could Double Your Money Heres Why They Could Jump (TipRanks)
Jun-12-23 08:30AM	Tarsus to Host Virtual Investor Webcast Highlighting the Commercialization Strategy, Plans and Progress for TP-03, Its Potential Treatment for Demodex Blepharitis (GlobeNewswire)
Jun-05-23 08:30AM	Tarsus to Present at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-09-23 04:05PM	Tarsus Reports First Quarter 2023 Financial Results and Recent Business Achievements (GlobeNewswire)
May-08-23 08:30AM	Tarsus Launches Dont Freak Out. Get Checked Out. Campaign During Healthy Vision Month to Encourage Patients with Demodex Blepharitis to Visit Eye Care Providers (GlobeNewswire)
May-05-23 08:22AM	Shareholders Should Be Pleased With Tarsus Pharmaceuticals, Inc.'s (NASDAQ:TARS) Price (Simply Wall St.)
May-03-23 04:30PM	Tarsus to Participate at the Bank of America 2023 Healthcare Conference (GlobeNewswire)
Apr-24-23 08:30AM	Tarsus Appoints Jeff Farrow as Chief Financial Officer and Chief Strategy Officer (GlobeNewswire)
Apr-18-23 06:04AM	Tarsus Pharmaceuticals, Inc. (TARS) Soars 8.6%: Is Further Upside Left in the Stock? (Zacks) +5.25%
Apr-06-23 03:52PM	Shareholders in Tarsus Pharmaceuticals (NASDAQ:TARS) are in the red if they invested a year ago (Simply Wall St.)
Mar-17-23 06:28AM	Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Is Expected To Breakeven In The Near Future (Simply Wall St.)
Mar-13-23 04:05PM	Tarsus Reports Full-Year 2022 Financial Results and Recent Business Achievements (GlobeNewswire)
Mar-09-23 10:00AM	Will Provention Bio, Inc. (PRVB) Report Negative Earnings Next Week? What You Should Know (Zacks)
Mar-02-23 04:30PM	Tarsus to Present at Upcoming Investor Conferences (GlobeNewswire)
Feb-24-23 11:44AM	Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) insiders placed bullish bets worth US$1.6m in the last 12 months (Simply Wall St.)
Jan-24-23 04:33AM	Strength Seen in Tarsus Pharmaceuticals, Inc. (TARS): Can Its 5.0% Jump Turn into More Strength? (Zacks)
Dec-16-22 07:00AM	Tarsus Added to NASDAQ Biotechnology Index (GlobeNewswire)
Dec-15-22 12:45PM	Tarsus Pharma Touts Positive Data For Experimental Drug For Tick-Borne Disease (Benzinga)
08:30AM	Tarsus Announces Positive Topline Data from Phase 1b Callisto Trial and Initiates Phase 2a Carpo Human Tick Kill Trial Evaluating TP-05, A Novel, Oral Therapeutic for the Prevention of Lyme Disease (GlobeNewswire)
Dec-08-22 06:55AM	Institutional investors own a significant stake of 41% in Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) (Simply Wall St.)
Nov-11-22 06:03AM	Tarsus Pharmaceuticals Third Quarter 2022 Earnings: US$0.84 loss per share (vs US$0.76 loss in 3Q 2021) (Simply Wall St.)
Nov-09-22 08:45AM	Tarsus Pharmaceuticals, Inc. (TARS) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Tarsus Reports Third Quarter 2022 Financial Results and Recent Business Achievements (GlobeNewswire)
Oct-25-22 08:30AM	Tarsus to Present Additional Saturn-2 Pivotal Phase 3 Trial Data at the American Academy of Optometry 2022 Annual Meeting (GlobeNewswire)
Oct-17-22 09:26AM	Tarsus Pharmaceuticals (NASDAQ:TARS) investors are sitting on a loss of 40% if they invested a year ago (Simply Wall St.)
Oct-11-22 08:30AM	Tarsus Announces Transition Plans for Board of Directors (GlobeNewswire)
Oct-06-22 08:30AM	Tarsus Appoints Scott Morrison as Board Member and Audit Committee Chair (GlobeNewswire)
Sep-29-22 08:30AM	Tarsus Launches Look at the Lids Campaign to Encourage Eye Care Professionals to Identify and Diagnose Demodex Blepharitis (GlobeNewswire)
Sep-27-22 12:00PM	Tarsus to Present Saturn-2 Pivotal Phase 3 Trial Data and Saturn-1 Extension Study Long-Term Safety Data Evaluating TP-03 for the Treatment of Demodex Blepharitis at Upcoming Eye Care Meetings (GlobeNewswire)
Sep-17-22 10:23AM	The Chief Medical Advisor & Director of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), Elizabeth Lin, Just Bought A Few More Shares (Simply Wall St.)
Sep-07-22 07:00AM	Tarsus Submits New Drug Application to the FDA for TP-03 for the Treatment of Demodex Blepharitis (GlobeNewswire)
Aug-11-22 05:25PM	Tarsus Pharmaceuticals, Inc. (TARS) Reports Q2 Loss, Misses Revenue Estimates (Zacks) +6.81%
04:05PM	Tarsus Reports Second Quarter 2022 Financial Results and Recent Business Achievements (GlobeNewswire)
Aug-05-22 08:30AM	Tarsus Initiates Phase 2a Ersa Trial Evaluating TP-03 for the Treatment of Meibomian Gland Disease (GlobeNewswire)
Jul-25-22 08:00AM	Certara Appoints Rosemary Crane as New Independent Board Member (GlobeNewswire)
Jun-29-22 06:51AM	Do Insiders Own Lots Of Shares In Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS)? (Simply Wall St.)
May-27-22 09:00AM	Tarsus to Present at the Jefferies 2022 Healthcare Conference (GlobeNewswire)
May-14-22 08:19AM	Analysts Just Shipped A Captivating Upgrade To Their Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Estimates (Simply Wall St.)
May-11-22 06:30AM	The Co-Founder & Independent Chairperson of the Board of Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS), D. Ackermann, Just Bought 8.3% More Shares (Simply Wall St.)
May-10-22 06:55PM	Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Misses Revenue Estimates (Zacks) +11.30%
04:05PM	Tarsus Reports First Quarter 2022 Financial Results and Recent Business Achievements (GlobeNewswire)
May-09-22 01:49PM	Further weakness as Tarsus Pharmaceuticals (NASDAQ:TARS) drops 39% this week, taking one-year losses to 63% (Simply Wall St.)
May-06-22 09:00AM	Tarsus to Present at Bank of America 2022 Healthcare Conference (GlobeNewswire) -8.05%
May-05-22 08:30AM	Tarsus Presents New Findings from Two Studies Demonstrating the Impact of Demodex Blepharitis at the ARVO 2022 Annual Meeting (GlobeNewswire) -6.73%
May-03-22 03:00PM	Tarsus Pharmaceuticals, Inc. (TARS) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release (Zacks) -6.79%
06:58AM	Tarsus Announces Pricing of Upsized $75.6 Million Underwritten Public Offering of Common Stock (GlobeNewswire)
May-02-22 07:01AM	Tarsus Announces Proposed $50 Million Underwritten Public Offering of Shares of its Common Stock (GlobeNewswire) -23.54%
07:00AM	Tarsus Announces Positive Topline Data from Saturn-2 Phase 3, the Second Pivotal Trial of TP-03 for the Treatment of Demodex Blepharitis, and Expects to File a New Drug Application This Year (GlobeNewswire)

Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of therapeutic candidates. Its product candidate, TP-03, is a novel therapeutic in Phase 2b/3 that is being developed for the treatment of blepharitis caused by the infestation of Demodex mites, which is referred to as Demodex blepharitis. The company was founded by Bobak Azamian and D. Michael Ackermann in 2017 and is headquartered in Irvine, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
LINK WILLIAM J PHD	Director	Aug 12 '24	Sale	26.08	35,000	912,961	0	Aug 14 04:34 PM
FLYING L PARTNERS XI LLC	Director	Aug 12 '24	Proposed Sale	26.85	35,000	939,750		Aug 12 04:25 PM
Farrow Jeffrey S	See Remarks	Jun 18 '24	Sale	27.47	10,445	286,924	18,136	Jun 20 04:26 PM
Mottiwala Aziz	Chief Commercial Officer	Mar 18 '24	Sale	30.60	4,766	145,840	54,075	Mar 19 07:08 PM
Wahl Bryan	General Counsel	Mar 18 '24	Sale	30.60	4,436	135,742	40,951	Mar 19 07:05 PM
Azamian Bobak R.	President/CEO and Board Chair	Mar 18 '24	Sale	30.60	10,415	318,699	26,456	Mar 19 07:05 PM
Whitfield Dianne C.	Chief Human Resources Officer	Mar 18 '24	Sale	30.60	4,314	132,008	34,181	Mar 19 07:04 PM
Neervannan Seshadri	Chief Operating Officer	Mar 18 '24	Sale	30.60	4,879	149,297	64,767	Mar 19 07:03 PM
Azamian Bobak R.	President/CEO and Board Chair	Dec 27 '23	Sale	20.22	8,000	161,760	830,106	Dec 29 05:08 PM
Trevejo Jose M.	CHIEF MEDICAL OFFICER	Dec 20 '23	Sale	20.00	2,252	45,040	2,251	Dec 22 05:32 PM
Azamian Bobak R.	President/CEO and Board Chair	Dec 20 '23	Sale	20.27	40,000	810,623	838,106	Dec 22 05:30 PM
Goldberg Andrew D.	Director	Dec 15 '23	Buy	18.96	1,000	18,960	3,000	Dec 19 06:30 PM
Whitfield Dianne C.	Chief Human Resources Officer	Nov 29 '23	Option Exercise	0.00	23,920	0	35,139	Dec 01 04:58 PM
Whitfield Dianne C.	Chief Human Resources Officer	Nov 30 '23	Sale	16.31	8,355	136,270	26,784	Dec 01 04:58 PM
Wahl Bryan	General Counsel	Nov 29 '23	Option Exercise	0.00	23,920	0	40,322	Dec 01 04:55 PM
Wahl Bryan	General Counsel	Nov 30 '23	Sale	16.31	8,356	136,286	31,966	Dec 01 04:55 PM
Azamian Bobak R.	President/CEO and Board Chair	Nov 15 '23	Sale	18.37	8,000	146,933	878,106	Nov 17 04:50 PM
Azamian Bobak R.	President/CEO and Board Chair	Oct 18 '23	Sale	13.24	8,000	105,920	886,106	Oct 20 04:41 PM
Trevejo Jose M.	CHIEF MEDICAL OFFICER	Oct 05 '23	Sale	18.00	1,604	28,872	4,503	Oct 06 05:21 PM

Open in Screener

RXST

RxSight Inc

Sep 20 • 04:00PM ET

52.98

Dollar change -0.59
Percentage change -1.10	%

Healthcare • Medical Devices • USA • NASD

Chart Stock Detail • Compare Perf. • Short Interest • Financials • Options • Save to Portfolio • Create Alert

Held by: VTI IWM VXF IWO VTWO DWAS SCHA VHT XHE PTH

Index	RUT	P/E	-	EPS (ttm)	-1.01	Insider Own	5.11%	Shs Outstand	39.68M	Perf Week	-3.60%
Market Cap	2.10B	Forward P/E	-	EPS next Y	-0.53	Insider Trans	-5.20%	Shs Float	37.66M	Perf Month	-1.29%
Income	-36.77M	PEG	-	EPS next Q	-0.23	Inst Own	83.25%	Short Float	6.07%	Perf Quarter	-6.63%
Sales	115.18M	P/S	18.25	EPS this Y	42.06%	Inst Trans	-0.95%	Short Ratio	4.04	Perf Half Y	3.64%
Book/sh	6.95	P/B	7.63	EPS next Y	35.67%	ROA	-14.69%	Short Interest	2.29M	Perf Year	86.81%
Cash/sh	5.88	P/C	9.01	EPS next 5Y	-	ROE	-17.01%	52W Range	20.66 - 66.54	Perf YTD	31.40%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-12.86%	52W High	-20.38%	Beta	1.21
Dividend TTM	-	Quick Ratio	13.34	Sales past 5Y	201.89%	Gross Margin	66.26%	52W Low	156.44%	ATR (14)	2.23
Dividend Ex-Date	-	Current Ratio	14.33	EPS Y/Y TTM	49.16%	Oper. Margin	-36.78%	RSI (14)	47.70	Volatility	3.84% 4.03%
Employees	374	Debt/Eq	0.04	Sales Y/Y TTM	71.90%	Profit Margin	-31.93%	Recom	1.00	Target Price	65.12
Option/Short	Yes / Yes	LT Debt/Eq	0.04	EPS Q/Q	60.48%	Payout	-	Rel Volume	2.41	Prev Close	53.57
Sales Surprise	7.92%	EPS Surprise	28.22%	Sales Q/Q	67.65%	Earnings	Aug 05 AMC	Avg Volume	566.46K	Price	52.98
SMA20	-3.10%	SMA50	4.42%	SMA200	3.48%	Trades		Volume	1,364,907	Change	-1.10%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-20-24	Reiterated	Needham	Buy	$54 → $66
Aug-06-24	Reiterated	Needham	Buy	$75 → $54
May-07-24	Reiterated	BTIG Research	Buy	$61 → $72
Dec-13-23	Upgrade	Wells Fargo	Equal Weight → Overweight	$31 → $42
Dec-12-23	Initiated	Stifel	Buy	$40
Dec-04-23	Initiated	Morgan Stanley	Overweight	$36
Apr-13-23	Initiated	Oppenheimer	Outperform	$23
Dec-12-22	Downgrade	Wells Fargo	Overweight → Equal Weight	$20 → $14
Apr-08-22	Initiated	Needham	Buy	$18

Aug-22-24 04:05PM	RxSight, Inc. to Participate in Upcoming Morgan Stanley and Wells Fargo Healthcare Conferences (GlobeNewswire)
Aug-19-24 03:43PM	RxSight Stock Sees Relative Strength Rating Rise To 91 (Investor's Business Daily)
Aug-12-24 09:55AM	Does RxSight (RXST) Have the Potential to Rally 27.64% as Wall Street Analysts Expect? (Zacks)
Aug-06-24 09:55AM	Q2 2024 Rxsight Inc Earnings Call (Thomson Reuters StreetEvents) +17.34%
Aug-05-24 06:10PM	RxSight, Inc. (RXST) Reports Break-Even Earnings for Q2 (Zacks)
04:05PM	Loading…
04:05PM	RxSight, Inc. Reports Second Quarter 2024 Financial Results (GlobeNewswire)
11:20AM	The 3 Best Med Tech Stocks to Buy Now (InvestorPlace)
Jul-29-24 09:35AM	Down -26.04% in 4 Weeks, Here's Why RxSight (RXST) Looks Ripe for a Turnaround (Zacks)
Jul-22-24 04:05PM	RxSight, Inc. to Report Second Quarter Financial Results on August 5, 2024 (GlobeNewswire)
Jul-12-24 09:35AM	RxSight (RXST) Loses -16.11% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Jul-10-24 10:59AM	Dow Flat As Nasdaq, S&P 500 Rise Again; Gold Stocks Rally, But These Growth Players Get Hit (Live Coverage) (Investor's Business Daily) -10.32%
Jun-18-24 01:50AM	Insider Sale: Director Julie Andrews Sells 15,625 Shares of RxSight Inc (RXST) (GuruFocus.com)
Jun-13-24 11:22AM	Eye Care Innovator In Buy Zone; 176% Growth Expected For IBD 50 Stock (Investor's Business Daily)
Jun-07-24 02:40PM	These 5 Companies Lost Money. Here's Why They're Still On The IBD 50. (Investor's Business Daily)
Jun-05-24 04:05PM	RxSight, Inc. To Participate in the Truist Securities Medtech Conference (GlobeNewswire)
04:00AM	Loading…
May-30-24 04:00AM	Oculis Publishes Results of 2024 Annual General Meeting and Announces Appointments to its Board of Directors and Scientific Advisory Board (GlobeNewswire)
May-28-24 12:00PM	What Makes RxSight, Inc. (RXST) a Strong Momentum Stock: Buy Now? (Zacks)
May-24-24 11:40AM	Why Top-Rated Medtech RxSight Has 20/20 Vision And Is Seeing 50% Growth (Investor's Business Daily)
May-13-24 04:58PM	RxSight Raises $115 Million From Public Offering of Shares (MT Newswires)
04:05PM	RxSight, Inc. Announces Closing of its Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
May-08-24 09:15PM	RxSight, Inc. Announces Pricing of Public Offering of Common Stock (GlobeNewswire)
04:05PM	RxSight, Inc. Announces Proposed Public Offering of Common Stock (GlobeNewswire)
May-07-24 12:17PM	Wells Fargo Adjusts RxSight Price Target to $68 From $61, Maintains Overweight Rating (MT Newswires)
08:50AM	RxSight, Inc. (NASDAQ:RXST) Q1 2024 Earnings Call Transcript (Insider Monkey)
08:49AM	Needham Adjusts Price Target on RxSight to $75 From $64, Maintains Buy Rating (MT Newswires)
08:48AM	Oppenheimer Adjusts RxSight Price Target to $72 From $61, Maintains Outperform Rating (MT Newswires)
08:28AM	BTIG Adjusts Price Target on RxSight to $72 From $61, Maintains Buy Rating (MT Newswires)
06:42AM	Q1 2024 Rxsight Inc Earnings Call (Thomson Reuters StreetEvents)
04:26AM	RxSight Q1 Adjusted Loss Narrows, Revenue Rises (MT Newswires)
03:10AM	RxSight Inc (RXST) Q1 2024 Earnings Call Transcript Highlights: Strong Revenue Growth and ... (GuruFocus.com)
05:37PM	Loading…
May-06-24 05:37PM	RxSight Inc (RXST) Surpasses Analyst Revenue Forecasts in Q1 2024 (GuruFocus.com)
05:06PM	Rxsight Insider Sold Shares Worth $2,405,872, According to a Recent SEC Filing (MT Newswires)
04:05PM	RxSight, Inc. Reports First Quarter 2024 Financial Results (GlobeNewswire)
May-02-24 05:03PM	Rxsight Insider Sold Shares Worth $526,913, According to a Recent SEC Filing (MT Newswires) +5.17%
May-01-24 04:05PM	RxSight, Inc. to Present at the Bank of America Healthcare Conference (GlobeNewswire) +8.77%
Apr-22-24 04:05PM	RxSight, Inc. to Report First Quarter Financial Results on May 6, 2024 (GlobeNewswire)
Apr-04-24 04:05PM	RxSight Announces Commercial Launch of its Newest Light Adjustable Lens , the LAL+ , and Features Multiple Doctor Presentations at the Upcoming ASCRS Annual Meeting (GlobeNewswire) +6.08%
Mar-27-24 04:05PM	RxSight, Inc. to Participate in the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Feb-29-24 07:05PM	RxSight, Inc. to Participate in the 34th Annual Oppenheimer Healthcare Conference (GlobeNewswire)
11:09AM	RxSight, Inc. (NASDAQ:RXST) Q4 2023 Earnings Call Transcript (Insider Monkey)
08:36AM	Q4 2023 Rxsight Inc Earnings Call (Thomson Reuters StreetEvents)
Feb-28-24 04:38PM	RxSight Inc (RXST) Reports Significant Revenue Growth in Q4 and Full Year 2023 (GuruFocus.com)
04:05PM	RxSight, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Feb-14-24 04:05PM	RxSight, Inc. to Report Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024 (GlobeNewswire)
Jan-19-24 05:01PM	Director Shweta Maniar Sells 6,399 Shares of RxSight Inc (GuruFocus.com)
Jan-12-24 03:16PM	3 Stocks to Buy BEFORE They Become Household Names (InvestorPlace)
Jan-09-24 06:19PM	RxSight, Inc. (RXST) Just Overtook the 20-Day Moving Average (Zacks)
Jan-07-24 10:00AM	RxSight, Inc. Announces Preliminary Unaudited Fourth Quarter and Full-Year 2023 Financial and Operational Results and 2024 Guidance (GlobeNewswire)
Dec-27-23 04:05PM	RxSight, Inc. to Present at the J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-15-23 09:30AM	RxSight, Inc. (RXST) Recently Broke Out Above the 50-Day Moving Average (Zacks)
Nov-12-23 10:26AM	RxSight, Inc. (NASDAQ:RXST) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-10-23 07:42AM	Q3 2023 Rxsight Inc Earnings Call (Thomson Reuters StreetEvents) +6.22%
Nov-09-23 04:05PM	RxSight, Inc. Reports Third Quarter 2023 Financial Results (GlobeNewswire)
Nov-02-23 09:00AM	RxSight, Inc. Educational and Product Announcements for AAO 2023 (GlobeNewswire)
Oct-26-23 04:05PM	RxSight, Inc. to Report Third Quarter Financial Results on November 9, 2023 (GlobeNewswire) -5.43%
Sep-07-23 09:35AM	RxSight, Inc. (RXST) Crossed Above the 20-Day Moving Average: What That Means for Investors (Zacks)
Aug-23-23 04:05PM	RxSight, Inc. to Present at the Wells Fargo Healthcare Conference (GlobeNewswire)
Aug-22-23 05:20PM	Has Alcon (ALC) Outpaced Other Medical Stocks This Year? (Zacks)
Aug-18-23 09:23AM	The Zacks Analyst Blog Highlights Abcam, Integer Holdings and RxSight (Zacks)
Aug-17-23 08:37AM	3 Medical Device Stocks With Potential to Fight Deflation Risk (Zacks)
Aug-08-23 08:44AM	RxSight, Inc. (NASDAQ:RXST) Q2 2023 Earnings Call Transcript (Insider Monkey)
06:21AM	Q2 2023 Rxsight Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-07-23 06:15PM	RxSight, Inc. (RXST) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:05PM	RxSight, Inc. Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Jul-25-23 04:05PM	RxSight, Inc. to Report Second Quarter Financial Results on August 7, 2023 (GlobeNewswire)
Jun-30-23 08:31AM	Strength Seen in RxSight, Inc. (RXST): Can Its 9.6% Jump Turn into More Strength? (Zacks)
Jun-27-23 08:38AM	Alphatec (ATEC) Surges 8.8%: Is This an Indication of Further Gains? (Zacks)
Jun-18-23 10:53AM	Investors in RxSight (NASDAQ:RXST) have seen respectable returns of 79% over the past year (Simply Wall St.)
May-10-23 07:52AM	Q1 2023 Rxsight Inc Earnings Call (Thomson Reuters StreetEvents) +9.87%
May-09-23 06:15PM	RxSight, Inc. (RXST) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:05PM	RxSight, Inc. Reports First Quarter 2023 Financial Results (GlobeNewswire)
May-03-23 10:00AM	Steris (STE) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
May-02-23 10:02AM	Will RxSight, Inc. (RXST) Report Negative Earnings Next Week? What You Should Know (Zacks)
Apr-26-23 06:33PM	2 Strong Buy Stocks Oppenheimer Predicts Will Surge at Least 30% (TipRanks)
04:05PM	RxSight, Inc. to Present at the Bank of America Healthcare Conference (GlobeNewswire)
Apr-25-23 04:05PM	RxSight, Inc. to Report First Quarter Financial Results on May 9, 2023 (GlobeNewswire)
Apr-24-23 04:05PM	Multiple Surgeon Presentations to Highlight RxSight® Light Adjustable Lens System at Upcoming American Society of Cataract and Refractive Surgery Annual Meeting (GlobeNewswire)
Apr-18-23 11:26AM	RxSight, Inc. (NASDAQ:RXST) Not Lagging Industry On Growth Or Pricing (Simply Wall St.)
Apr-11-23 12:00PM	Here's Why RxSight, Inc. (RXST) is a Great Momentum Stock to Buy (Zacks)
Apr-05-23 04:05PM	RxSight, Inc. to Present at the Needham Healthcare Conference (GlobeNewswire)
Mar-13-23 09:55AM	How Much Upside is Left in RxSight, Inc. (RXST)? Wall Street Analysts Think 25.69% (Zacks)
Mar-08-23 07:21AM	RxSight, Inc. (NASDAQ:RXST) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-07-23 08:23AM	Q4 2022 Rxsight Inc Earnings Call (Thomson Reuters StreetEvents)
05:16AM	RxSight, Inc.'s (NASDAQ:RXST) biggest owners are individual investors who got richer after stock soared 14% last week (Simply Wall St.)
Mar-06-23 04:05PM	RxSight, Inc. Reports Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire) +12.96%
Feb-28-23 04:05PM	RxSight, Inc. to Present at the Oppenheimer Healthcare Conference (GlobeNewswire)
Feb-21-23 04:05PM	RxSight, Inc. to Report Fourth Quarter and Fiscal Year 2022 Financial Results on March 6, 2023 (GlobeNewswire)
Feb-14-23 04:05PM	RxSight, Inc. Announces Full Exercise of Underwriters Option to Purchase Additional Shares and Closing of its Public Offering of Common Stock (GlobeNewswire)
Feb-08-23 12:45AM	RxSight, Inc. Announces Pricing of Public Offering of Common Stock (GlobeNewswire) -7.70%
Feb-07-23 04:05PM	RxSight, Inc. Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Jan-09-23 08:56AM	Investing in RxSight (NASDAQ:RXST) a year ago would have delivered you a 12% gain (Simply Wall St.)
Jan-08-23 04:00PM	RxSight, Inc. Announces Preliminary Unaudited Fourth Quarter and Full Year 2022 Financial and Operational Results (GlobeNewswire)
Dec-31-22 06:15AM	RxSight, Inc. (NASDAQ:RXST) Q3 2022 Earnings Call Transcript (Insider Monkey)
Dec-28-22 04:05PM	RxSight, Inc. to Present at the J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-22-22 09:40AM	Has IntraCellular Therapies (ITCI) Outpaced Other Medical Stocks This Year? (Zacks) +5.33%
Dec-06-22 09:40AM	Is RxSight (RXST) Stock Outpacing Its Medical Peers This Year? (Zacks) -7.66%
Dec-02-22 09:55AM	Does RxSight, Inc. (RXST) Have the Potential to Rally 43% as Wall Street Analysts Expect? (Zacks)
Nov-16-22 09:55AM	Wall Street Analysts Predict a 45% Upside in RxSight, Inc. (RXST): Here's What You Should Know (Zacks)
Nov-09-22 06:10AM	RxSight Third Quarter 2022 Earnings: Beats Expectations (Simply Wall St.)
Nov-07-22 06:15PM	RxSight, Inc. (RXST) Reports Q3 Loss, Tops Revenue Estimates (Zacks) +7.86% +6.74%

RxSight, Inc. engages in the research, development, manufacture, and sale of light adjustable lenses and related capital equipment. It also commercializes adjustable intraocular lens (IOL) that is customized after cataract surgery. The company was founded on March 5, 1997 and is headquartered in Aliso Viejo, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
ILYA GOLDSHLEGER	Officer	Sep 20 '24	Proposed Sale	53.19	3,100	164,901		Sep 20 04:08 PM
Goldshleger Ilya	See remarks	Sep 17 '24	Option Exercise	15.08	3,100	46,748	45,346	Sep 18 04:41 PM
Goldshleger Ilya	See remarks	Sep 17 '24	Sale	56.11	3,100	173,944	42,246	Sep 18 04:41 PM
ILYA GOLDSHLEGER	Officer	Sep 17 '24	Proposed Sale	56.11	3,100	173,943		Sep 17 04:15 PM
Kurtz Ronald M MD	President & CEO	Aug 09 '24	Option Exercise	12.60	9,950	125,355	63,450	Aug 09 05:57 PM
Goldshleger Ilya	See remarks	Aug 05 '24	Sale	39.25	9,000	353,291	42,246	Aug 06 04:19 PM
ILYA GOLDSHLEGER	Officer	Aug 05 '24	Proposed Sale	39.25	9,000	353,290		Aug 05 04:08 PM
Thunen Shelley B	See remarks	Jul 15 '24	Option Exercise	4.34	16,505	71,632	30,443	Jul 16 08:15 PM
Kurtz Ronald M MD	President & CEO	Jul 11 '24	Option Exercise	15.08	13,500	203,604	53,500	Jul 12 07:12 PM
Thunen Shelley B	Chief Financial Officer	Jul 01 '24	Option Exercise	15.60	10,000	155,983	23,938	Jul 02 04:25 PM
Thunen Shelley B	Chief Financial Officer	Jul 01 '24	Sale	58.61	10,000	586,055	13,938	Jul 02 04:25 PM
Thunen Shelley B	Chief Financial Officer	Jul 01 '24	Sale	58.77	8,402	493,760	0	Jul 02 04:25 PM
Andrews Julie	Director	Jun 14 '24	Sale	58.00	15,625	906,288	30,287	Jun 17 06:45 PM
Tammenoms Bakker Juliet	Director	May 17 '24	Buy	61.09	5,000	305,456	34,840	May 21 04:11 PM
Goldshleger Ilya	Chief Operating Officer	May 17 '24	Option Exercise	4.04	24,771	100,066	51,246	May 20 04:56 PM
Kurtz Ronald M MD	President & CEO	May 03 '24	Sale	60.15	40,000	2,405,872	764,610	May 06 05:02 PM
Thunen Shelley B	Chief Financial Officer	May 01 '24	Option Exercise	15.60	10,247	159,836	23,938	May 02 04:58 PM
Thunen Shelley B	Chief Financial Officer	May 01 '24	Sale	52.69	10,000	526,913	13,938	May 02 04:58 PM
Thunen Shelley B	Chief Financial Officer	Apr 01 '24	Sale	49.90	20,000	997,946	8,402	Apr 02 04:18 PM
Thunen Shelley B	Chief Financial Officer	Mar 01 '24	Option Exercise	15.60	10,000	155,983	23,691	Mar 05 04:05 PM
Thunen Shelley B	Chief Financial Officer	Mar 01 '24	Sale	56.37	10,000	563,726	13,691	Mar 05 04:05 PM
Goldshleger Ilya	Chief Operating Officer	Feb 16 '24	Option Exercise	23.04	10,000	230,400	36,475	Feb 16 05:00 PM
Goldshleger Ilya	Chief Operating Officer	Feb 15 '24	Option Exercise	23.04	10,000	230,400	36,475	Feb 16 05:00 PM
Goldshleger Ilya	Chief Operating Officer	Feb 14 '24	Option Exercise	23.04	5,000	115,200	31,475	Feb 16 05:00 PM
Goldshleger Ilya	Chief Operating Officer	Feb 16 '24	Sale	55.50	10,000	555,000	26,475	Feb 16 05:00 PM
Goldshleger Ilya	Chief Operating Officer	Feb 15 '24	Sale	53.50	10,000	535,000	26,475	Feb 16 05:00 PM
Goldshleger Ilya	Chief Operating Officer	Feb 14 '24	Sale	52.00	5,000	260,000	26,475	Feb 16 05:00 PM
Tammenoms Bakker Juliet	Director	Feb 14 '24	Buy	51.29	4,000	205,153	29,840	Feb 15 04:15 PM
Tammenoms Bakker Juliet	Director	Feb 12 '24	Buy	50.38	4,000	201,520	25,840	Feb 15 04:15 PM
Goldshleger Ilya	Chief Operating Officer	Feb 09 '24	Option Exercise	20.90	10,365	216,598	36,840	Feb 12 06:02 PM
Goldshleger Ilya	Chief Operating Officer	Feb 09 '24	Sale	50.74	10,365	525,939	26,475	Feb 12 06:02 PM
Thunen Shelley B	Chief Financial Officer	Feb 06 '24	Option Exercise	14.95	15,875	237,331	29,566	Feb 07 05:18 PM
Thunen Shelley B	Chief Financial Officer	Feb 05 '24	Option Exercise	10.38	16,025	166,365	22,816	Feb 07 05:18 PM
Thunen Shelley B	Chief Financial Officer	Feb 06 '24	Sale	47.47	15,875	753,574	13,691	Feb 07 05:18 PM
Thunen Shelley B	Chief Financial Officer	Feb 05 '24	Sale	47.02	9,125	429,087	13,691	Feb 07 05:18 PM
LINK WILLIAM J PHD	Director	Feb 01 '24	Sale	49.67	28,250	1,403,120	24,248	Feb 02 04:49 PM
Goldshleger Ilya	Chief Operating Officer	Feb 01 '24	Option Exercise	19.24	7,129	137,181	33,604	Feb 02 04:47 PM
Goldshleger Ilya	Chief Operating Officer	Feb 01 '24	Sale	49.29	7,129	351,411	26,475	Feb 02 04:47 PM
Weinberg Eric	Chief Commercial Officer	Feb 01 '24	Sale	50.00	10,000	500,004	299,978	Feb 02 04:47 PM
Thunen Shelley B	Chief Financial Officer	Jan 26 '24	Option Exercise	13.75	36,272	498,652	38,563	Jan 29 05:36 PM
Thunen Shelley B	Chief Financial Officer	Jan 26 '24	Sale	47.11	31,772	1,496,706	6,791	Jan 29 05:36 PM
Weinberg Eric	Chief Commercial Officer	Jan 22 '24	Sale	48.00	10,000	480,006	309,978	Jan 22 07:50 PM
Goldshleger Ilya	Chief Operating Officer	Jan 22 '24	Option Exercise	18.90	5,000	94,500	31,475	Jan 22 07:48 PM
Goldshleger Ilya	Chief Operating Officer	Jan 22 '24	Sale	48.00	5,000	240,000	26,475	Jan 22 07:48 PM
Maniar Shweta	Director	Jan 18 '24	Sale	45.72	6,399	292,555	12,130	Jan 19 04:01 PM
Goldshleger Ilya	Chief Operating Officer	Jan 09 '24	Option Exercise	18.90	5,000	94,500	31,475	Jan 10 05:29 PM
Goldshleger Ilya	Chief Operating Officer	Jan 09 '24	Sale	47.00	5,000	235,000	26,475	Jan 10 05:29 PM
Weinberg Eric	Chief Commercial Officer	Jan 09 '24	Sale	46.00	10,000	460,000	319,978	Jan 10 05:28 PM
Weinberg Eric	Chief Commercial Officer	Jan 08 '24	Sale	42.00	10,000	420,000	329,978	Jan 09 04:12 PM
Warner Robert Keith	Director	Jan 08 '24	Sale	42.69	23,750	1,013,894	0	Jan 09 04:10 PM
Maniar Shweta	Director	Jan 08 '24	Sale	45.00	6,418	288,810	18,529	Jan 09 04:09 PM
Kurtz Ronald M MD	President & CEO	Jan 08 '24	Sale	44.25	62,500	2,765,631	804,610	Jan 09 04:08 PM
Goldshleger Ilya	Chief Operating Officer	Jan 08 '24	Option Exercise	15.08	15,000	226,200	41,475	Jan 09 04:05 PM
Goldshleger Ilya	Chief Operating Officer	Jan 08 '24	Sale	43.33	15,000	650,000	26,475	Jan 09 04:05 PM
Corley Jesse Anderson	Director	Jan 08 '24	Sale	45.03	2,000	90,059	11,625	Jan 09 04:02 PM
Thunen Shelley B	Chief Financial Officer	Jan 02 '24	Option Exercise	15.60	10,000	155,983	12,291	Jan 03 04:11 PM
Thunen Shelley B	Chief Financial Officer	Jan 02 '24	Sale	39.24	10,000	392,409	2,291	Jan 03 04:11 PM
Kurtz Ronald M MD	President & CEO	Dec 27 '23	Sale	41.09	22,500	924,498	867,110	Dec 29 04:57 PM
Weinberg Eric	Chief Commercial Officer	Dec 22 '23	Sale	40.00	1,285	51,400	339,978	Dec 26 04:11 PM
Goldshleger Ilya	Chief Operating Officer	Dec 22 '23	Option Exercise	15.08	5,000	75,400	31,475	Dec 26 04:10 PM
Goldshleger Ilya	Chief Operating Officer	Dec 22 '23	Sale	40.00	5,000	200,000	26,475	Dec 26 04:10 PM
Goldshleger Ilya	Chief Operating Officer	Dec 18 '23	Option Exercise	14.14	10,937	154,670	37,412	Dec 20 06:07 PM
Goldshleger Ilya	Chief Operating Officer	Dec 18 '23	Sale	39.02	10,937	426,710	26,475	Dec 20 06:07 PM
Weinberg Eric	Chief Commercial Officer	Dec 15 '23	Sale	40.01	8,715	348,711	341,263	Dec 19 08:14 PM
Thunen Shelley B	Chief Financial Officer	Dec 15 '23	Option Exercise	15.60	20,000	312,000	22,291	Dec 18 07:09 PM
Thunen Shelley B	Chief Financial Officer	Dec 15 '23	Sale	39.35	20,000	786,984	2,291	Dec 18 07:09 PM
Thunen Shelley B	Chief Financial Officer	Dec 15 '23	Sale	39.32	20,000	786,326	28,402	Dec 18 07:09 PM
Corley Jesse Anderson	Director	Dec 14 '23	Sale	40.12	12,000	481,469	13,625	Dec 18 07:08 PM
Kurtz Ronald M MD	President & CEO	Dec 14 '23	Sale	39.70	40,000	1,588,186	889,610	Dec 18 07:07 PM
Warner Robert Keith	Director	Dec 08 '23	Sale	35.01	14,502	507,706	29,248	Dec 12 06:49 PM
Warner Robert Keith	Director	Dec 11 '23	Sale	35.08	5,498	192,845	23,750	Dec 12 06:49 PM
Tammenoms Bakker Juliet	Director	Nov 29 '23	Sale	29.77	349,245	10,398,665	0	Nov 30 07:32 PM
Tammenoms Bakker Juliet	Director	Nov 28 '23	Sale	29.62	145,068	4,297,030	349,245	Nov 30 07:32 PM
Tammenoms Bakker Juliet	Director	Nov 15 '23	Sale	27.20	400,000	10,878,160	494,313	Nov 16 07:31 PM
Tammenoms Bakker Juliet	Director	Nov 14 '23	Sale	27.13	100,000	2,712,590	894,313	Nov 16 07:31 PM

TARS

Tarsus Pharmaceuticals Inc

RXST

RxSight Inc

Upgrade your FINVIZ experience